Akèy › Kansè nan tete › Virginia › Norfolk
Etid klinik pou Kansè nan tete nan Norfolk, VA
16 etid pou Kansè nan tete ap chèche patisipan nan sit nan ak bò kote Norfolk (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Ap rekriteFaz 3
- Virginia Oncology Associates, Norfolk
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Sentara Norfolk General Hospital, Norfolk
A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
Ap rekriteFaz 1/2
- Virginia Oncology Associates, Norfolk
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
Ap rekriteFaz 2
- Virginia Oncology Associates, Norfolk
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Ap rekriteFaz 3
- Virginia Oncology Associates (VOA) ( Site 8001), Norfolk
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Ap rekriteFaz 3
- Virginia Oncology Associates (VOA) ( Site 8008), Norfolk
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
Ap rekriteFaz 3
- Research Site, Norfolk
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Ap rekriteFaz 3
- Clinical Trial Site, Norfolk
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
Ap rekriteFaz 2
- Virginia Oncology Associates (VOA) ( Site 8001), Norfolk
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
Ap rekriteFaz 1/2
- Virginia Cancer Institute, Norfolk
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
Ap rekriteFaz 1/2
- Virginia Oncology Associates (Norfolk) - USOR, Norfolk
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Ap rekriteFaz 3
- Virginia Oncology Associates, Norfolk
The Vanguard Study: Testing a New Way to Screen for Cancer
Ap rekriteVolontè an sante akeyi
- Sentara Norfolk General Hospital, Norfolk
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Ap rekriteFaz 3
- Virginia Oncology Associates, Norfolk
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Ap rekriteFaz 1/2
- USOR Virginia Oncology Associates, Norfolk
Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
Ap rekriteFaz 2
- Virginia Oncology Associates, Norfolk
Etid Kansè nan tete nan lòt vil
- New York City, NY134 etid
- Houston, TX126 etid
- Boston, MA111 etid
- Nashville, TN80 etid
- Los Angeles, CA72 etid
- Edison, NJ68 etid
- St. Louis, MO64 etid
- Durham, NC63 etid
- Queens, NY63 etid
- Chicago, IL58 etid
- Philadelphia, PA56 etid
- Dallas, TX55 etid
Lòt etid nan Norfolk
- Kansè pwostat8 etid
- Kansè vejik8 etid
- Kansè ovè7 etid
- Kansè Poumon ki pa ti selil7 etid
- Aneurism aòtik abdominal7 etid
- Ensifizyans kadyak7 etid
- Kansè (tout kalite)7 etid
- Maladi kadyovaskilè7 etid
- Atrofi miskilè spinal6 etid
- Maladi atè perifèrik5 etid
- Kansè tete negatif triple5 etid
- Leksemi limfoblastik egi5 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.